Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Reports Flat Q4 Sales as Thermal Cycler Injunction Took Its Toll

NEW YORK, Feb. 23 (GenomeWeb News) - Bio-Rad yesterday said that fourth-quarter net sales were flat, with $307.3 million for the period ended Dec. 31, compared to $307.9 in the year-ago period.

 

Net sales show a 2.9-percent rise from the similar period in 2004 when earnings are adjusted for currency-exchange effects, the company said.

 

The company's Life Science segment experienced a 5.3-percent drop in net sales, which fell to $140.7 million from $148.6 million in the fourth quarter of 2004. Bio-Rad attributed the decline to an injunction that halted the sale and manufacture of its MJ Research thermal cyclers..

 

Bio-Rad's Clinical Diagnostics segment reported net sales of $162.9 million for the period ended Dec. 31, a rise of 4 percent year over year.

 

R&D expenses remained nearly unchanged at $31.9 million for the current period, versus $31.1 million in the year-ago period.

 

Net income decreased to $13.5 million in the fourth quarter from $17.1 million in 2004.

 

The company had around $296.7 million in cash and equivalents as of Dec. 31.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.